Diazepam is one of the most prescribed benzodiazepines. The purpose of the present research was to optimize the formulation of orodispersible tablets of diazepam. Orodispersible tablets of diazepam were prepared using different types of superdisintegrants (Ac-Di-Sol, sodium starch glycolate, and crospovidone (CP)) and different types of subliming agents (camphor and ammonium bicarbonate (AB)) at different concentrations and two methods of tablets preparations (wet granulation and direct compression methods). The formulations were evaluated for flow properties, wetting time, hardness, friability, content uniformity, in vivo disintegration time (DT), release profiles, and buccal absorption tests. All formulations showed satisfactory mechanical strength except formula F5 which contains camphor and formula F9 which is prepared by direct compression method. The results revealed that the tablets containing CP as a superdisintegrant have good dissolution profile with shortest DT. The optimized formula F7 is prepared using 10% CP as a superdisintegrant and 20% AB as a subliming agent by wet granulation method which shows the shortest DT and good dissolution profile with acceptable stability. This study helps in revealing the effect of formulation processing variables on tablet properties. It can be concluded that the orodispersible tablets of diazepam with better biopharmaceutical properties than conventional tablets could be obtained using formula F7.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850478 | PMC |
| http://dx.doi.org/10.1208/s12249-010-9387-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: an Open-Label Extension Study.
Clin Gastroenterol Hepatol
December 2024
Health Services Research, Durham University, Durham, United Kingdom.
Background And Aims: Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase 3 double-blind trials of induction and 48-week maintenance therapy of eosinophilic esophagitis (EoE). We now analyzed the long-term efficacy and safety of BOT in a 96-week open-label extension (OLE) study.
Methods: All EoE patients in the 48-week double-blind maintenance study were eligible to receive BOT treatment for up to 96 weeks.
A review of precision medicine in developing pharmaceutical products: Perspectives and opportunities.
Int J Pharm
December 2024
Pharmacogenomics (PGx) Laboratory, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, 00936, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico - Medical Sciences Campus, San Juan, PR 00936, United States. Electronic address:
Over the next decade, Precision Medicine (PM) is poised to become the standard of care in pharmaceutical therapy, necessitating a fundamental transformation in the design and development of innovative custom-made drug products. To date, a comprehensive review linking PM with practical personalized drug formulations is missing. This review attempts to provide an overview of state-of-the-art formulation approaches capable of translating PM evaluation and resulting recommendations (clinical research) into tailored drug products (non-clinical research) for real-world patients.
View Article and Find Full Text PDFSwitch From Off-Label Swallowed Topical Corticosteroids to Budesonide Orodispersible Tablets in Eosinophilic Esophagitis Patients.
Clin Gastroenterol Hepatol
November 2024
Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson's disease.
Ther Adv Neurol Disord
October 2024
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
Background: Limited treatment options with a rapid onset of action are available to treat off episodes in Parkinson's disease (PD) patients. Therefore, the development of rapid onset formulations, for instance with levodopa, is warranted, which was the reason to investigate an inhalable formulation of levodopa.
Objectives: The primary objective was to determine the duration until maximum effect is reached of inhaled levodopa on the improvement of motor function of PD patients.
Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
Inflamm Intest Dis
July 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic condition driven by food allergies that causes changes in the esophagus, necessitating treatment options like medications, dietary changes, and dilation.
- Recently approved treatments include oral budesonide tablets (Jorveza) in Europe, Canada, and Australia, and an orodispersible budesonide suspension (Eohilia) in the USA, both shown to effectively induce and maintain remission in EoE patients.
- Other treatment considerations include off-label proton-pump inhibitors, which have inconsistent results, and Dupilumab, a monoclonal antibody approved for EoE treatment in multiple regions, available for older adolescents and adults who don't respond to
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!